Welcome to our dedicated page for Ensysce Biosciences SEC filings (Ticker: ENSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ensysce Biosciences, Inc. (NASDAQ: ENSC) SEC filings page provides access to the company’s official regulatory disclosures, including current reports, registration statements, and other documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage pharmaceutical company focused on TAAP™ and MPAR®-based therapeutics for severe pain, ADHD, and opioid use disorder, Ensysce uses these filings to report material agreements, financings, clinical and regulatory milestones, and financial results.
Investors reviewing ENSC filings will find Form 8-K current reports detailing events such as preferred stock and warrant financings, like the Securities Purchase Agreement for Series B Preferred Stock and related warrants described in the November 17, 2025 8-K. These filings outline terms including conversion prices, warrant exercise prices, exchange caps under Nasdaq rules, and intended use of proceeds, which the company states includes continued development of its TAAP™ and MPAR® programs and working capital.
Other 8-K filings reference press releases announcing quarterly financial results, where Ensysce summarizes grant funding, research and development expenses, and progress across PF614, PF614-MPAR, and related programs. Registration statements on Form S-3 and associated prospectus supplements, as cited in the company’s financing disclosures, provide additional detail on how Ensysce accesses the capital markets to support its clinical pipeline.
On Stock Titan, these ENSC filings are paired with AI-powered summaries that highlight key terms, structural features of financings, and the implications of material events for shareholders. Users can quickly understand the main points of lengthy documents, while still having direct access to the full text on EDGAR for deeper review. This page also helps track equity issuances, preferred stock designations, and other corporate actions that shape Ensysce’s capital structure as it advances its next-generation pain and CNS therapeutics.
Ensysce Biosciences, Inc. registers up to 20,335,491 shares of common stock for resale by selling securityholders. The resale pool consists of Conversion Shares issuable on conversion of Series B preferred stock and shares issuable upon exercise of multiple warrant series. The registration covers resale only; the company will not receive proceeds from these resales but will receive proceeds if the Investor Warrants are exercised for cash. The prospectus discloses 9,277,819 shares of common stock outstanding as of April 2, 2026, a reported last sale price of $0.6096 per share on April 2, 2026, a going concern explanatory paragraph in the 2025 audited financials and cash to fund operations into the second quarter of 2026. The filing details conversion-price adjustments, beneficial-ownership limits (4.99%/9.99%), extensive anti-dilution mechanics and resale methods permitted under the Plan of Distribution.
Ensysce Biosciences entered a new financing tranche, closing a private offering of $2 million in Series B preferred stock on April 6, 2026 under a 2025 commitment of up to $20 million over 24 months.
The company issued 2,000 Series B preferred shares convertible into up to 4,363,636 common shares at a fixed price of $0.55 per share, plus Warrants to purchase up to 8,727,273 common shares at the same price, with 18‑month and five‑year terms. Net proceeds of about $1.9 million are earmarked for general corporate purposes and development of its TAAP and MPAR® pain programs.
Ensysce Biosciences Inc. reported that board member Dr. Curtis Rosebraugh resigned from its Board of Directors, effective April 1, 2026. He also stepped down from the Board’s Nominating and Corporate Governance Committee. His written resignation notice is included as Exhibit 17 to the report.
Ensysce Biosciences is a clinical-stage pharmaceutical company developing abuse-resistant and overdose-protective opioid pain therapies using its TAAP and MPAR platforms. Lead drug PF614, an extended-release oxycodone prodrug, has completed multiple Phase 1 trials and human abuse potential studies, and a pivotal Phase 3 post-surgical pain trial began enrollment in December 2025.
Combination candidate PF614-MPAR, which adds nafamostat for overdose protection, has shown reduced oxycodone exposure in simulated overdose settings and received FDA Breakthrough Therapy designation in January 2024. The company highlights substantial ongoing losses, a need for significant additional funding, reliance on PF614 and PF614-MPAR, Nasdaq delisting risk, and extensive regulatory and intellectual property uncertainties.
Ensysce Biosciences reported fourth quarter and full year 2025 results alongside clinical and regulatory progress for its opioid safety pipeline. The company advanced lead pain candidate PF614 into a pivotal Phase 3 post‑surgical pain trial and continued development of PF614‑MPAR, which has FDA Breakthrough Therapy designation for its overdose‑protection technology.
PF614‑301 Phase 3 enrollment is underway, and the FDA provided supportive feedback for PF614‑MPAR, including potential use of a streamlined 505(b)(2) pathway and overdose‑protection labeling. Ensysce also expanded its intellectual property, with a new U.S. patent on MPAR® technology extending protection to 2042 and a European notice of allowance for an amphetamine prodrug patent.
Financially, federal grant funding was $5.1 million in 2025, while research and development expenses rose to $10.4 million and general and administrative costs were $4.9 million. Net loss attributable to common stockholders increased to $10.2 million for 2025, with fourth quarter loss of $2.8 million. Cash and cash equivalents were $4.3 million at December 31, 2025, supported by $8.7 million of net cash provided by financing activities. As a clinical‑stage biotech, the company expects continued losses as it invests in late‑stage trials and pipeline growth.
Ensysce Biosciences announced that board member Lee Rauch resigned from the Board of Directors effective March 24, 2026. She previously served on the Audit and Compensation Committees and chaired the Nominating and Corporate Governance Committee. Rauch’s resignation follows her disagreement with new retention and severance arrangements for certain managers and the Chief Financial Officer.
The company is considering strategic alternatives and approved three‑month severance packages for three managers and extended CFO Mr. Humphrey’s retention package from six to nine months. These protections apply if they are not retained in a strategic transaction or for one year afterward and provide releases of claims and reaffirmed restrictive covenants. The total estimated cost of these measures is about $205,475. Rauch voted against the packages and had expressed other disagreements with board actions before resigning.
Ensysce Biosciences, Inc. filed a Certificate of Correction with the State of Delaware on March 18, 2026 to fix a scrivener’s error in its Certificate of Designation for Series B Preferred Stock, which is part of its Certificate of Incorporation. The full correction text is provided in Exhibit 3.1.
Ensysce Biosciences received a Nasdaq notice that its common stock no longer meets the exchange’s minimum bid price requirement, because the share price has closed below $1.00 for 30 consecutive business days. This puts the company at risk of eventually losing its Nasdaq listing.
The company has 180 calendar days, until August 24, 2026, to regain compliance by having its stock close at or above $1.00 for at least ten consecutive business days. The notice does not immediately affect trading, and the shares continue to trade on the Nasdaq Capital Market under the symbol ENSC while the company monitors its bid price and evaluates options.
Ensysce Biosciences, Inc. held its annual stockholder meeting on January 7, 2026. Stockholders approved, for purposes of Nasdaq Listing Rule 5635(d), the full issuance of shares of common stock and the exercise of warrants for common stock issued to an investor. They also approved an amendment to the Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan, increasing the total number of shares that may be issued under the plan from 121,457 shares to 721,457 shares.
Stockholders elected two Class I directors, William Chang and Lee Rauch, to terms expiring at the 2028 annual meeting. In addition, they ratified the appointment of Baker Tilly US, LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. A fifth proposal to adjourn the meeting, if needed, was included in the proxy materials but was not submitted to a vote.